ViiV Healthcare press release
ViiV Healthcare announced week 96 and end‑of‑study results from the phase I/II IMPAACT 2017 (MOCHA) study, the first trial to evaluate a complete injectable long‑acting treatment regimen in adolescents living with HIV.
Results showed 94.4% of virologically suppressed adolescents aged 12 to <18 years who switched from daily oral HIV treatment to long-acting cabotegravir + rilpivirine (CAB + RPV LA) every two months maintained viral suppression at week 96, with >97% indicating a preference for injections over daily oral therapy at all weeks.
Read the full press release here.
Source : ViiV Healthcare
Related HIV and Co-Infections News
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.